Federal Food & Drug AdministrationNeuproParkinson's diseaseAnnouncement

FDA approval

9 May, 2007

The FDA announces the approval of Neupro, the first skin patch designed to treat symptoms of early Parkinson’s disease. Neupro patches, which are changed daily, deliver rotigotine through the skin. Rotigotine is a member of a class of drugs called dopamine agonists, which mimic dopamine’s effects.

Add your comments below...